Severe graft-versus-host disease is a lethal complication to allogeneic haemopoietic stem cell transplantation. This short review gives an overview of novel treatment strategies. Psoralen-enhanced UVA irradiation (PUVA), extracorpoal PUVA, antibodies against IL-2 and TNFalpha, thalidomide, octreotide, and mesenchymal stem cells are briefly discussed. Bone Marrow Transplantation (2005) 35, S65-S67.
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Standard GVHD prophylaxis and therapy
Today's standard GVHD prophylaxis regimens are based on the experience from several decades of allogeneic haematopoietic stem cell transplantation (allo-HSCT). Many centres are using a combination of cyclosporine A and a short course (four doses) of i.v. methotrexate (Mtx), which has proven to be superior to either drug alone. 1 Since the 1990s we have seen the arrival of new immunosuppressive drugs, which are now being more extensively used for prophylaxis. Examples of this include tacrolimus (FK-506), either alone or combined with Mtx as above; mycophenolate mofetil (MMF); rapamycin (sirolimus), the latter often in combination with MMF.
A retrospective EBMT study has determined that grade I acute GVHD is the optimal level for patients with malignant disease, at least in adult patients. 2 Accordingly, treatment for acute GVHD is commenced when patients reach grade I or II. First-line therapy consists of corticosteroids, usually prednisolone or methyl prednisolone in doses of 1-2 (-5) mg/kg body weight/day, depending on the severity. Immunosuppression as mentioned above should be at least maintained, if not increased. One or a few doses of ATG are also often added at this stage, but at the cost of an increased risk of relapse.
Refractory acute GVHD
Steroid refractory GVHD is a major problem, posing a substantial threat to the patient's life and well-being. Aggressive GVHD therapy is required and it is a rule rather than an exception that these patients run into severe adverse events resulting from the GVHD as well as its treatment. Acute GVHD involving more than the skin (ie grade II or higher) and refractory to steroids confers increased risks of systemic infection, respiratory failure, renal and/or hepatic failure, admission to Intensive Care Units, requirement for assisted ventilation and/or dialysis, and is frequently fatal.
The treatment for refractory acute GVHD is less than satisfactory, and a number of approaches are therefore being evaluated, with varying efficacy. Recent additions to the therapeutic arsenal include somatostatin analogues (octreotide) [3] [4] [5] ; monoclonal antibodies against cytokines involved in GVHD, mainly TNF-alpha and IL-2; PUVA (psoralen-enhanced UVA irradiation) 6 , extracorporeal photochemotherapy/PUVA (ECP) 7 and the use of third party expanded immunomodulatory cells. 8 A few of these are discussed below.
Novel therapies against GVHD (not in order of importance!)
PUVA This is likely to be a good option in steroid refractory chronic skin GVHD, but seems to also have some degree of activity in acute GVHD of the skin. 6 T cells in the dermis are rendered sensitive to UVA light by oral intake of a psoralen, and are then inactivated by cutaneous UVA irradiation. During PUVA treatment, cutaneous T cells lose the ability to migrate and to proliferate upon antigen stimulation. The mechanism for this is not clear. Therapy typically needs to be repeated weekly or biweekly until resolution or no evidence of improvement. Response is sometimes delayed, and a minimum of 4-6 doses is recommended before evaluation can be made.
Extracorporeal PUVA (photopheresis, ECP)
This is discussed in an adjacent article by J Kanold et al.
Cytokine antibodies
It is well established that proinflammatory cytokine signalling, mainly by IL-2 and TNF-alpha, is a key event in the early phases of GVHD. A way of preventing this is by the use of monoclonal antibodies directed against IL-2 receptor (daclizumab 9 , basiliximab 10 ) or TNF-alpha (infliximab 11 ). These antibodies are highly specific immunosuppressants with a different mode of action than the calcineurin inhibitors cyclosporine and tacrolimus. 12 Some centres use a combination of monoclonal antibodies against IL-2 and TNF-alpha. Results from pilot studies are promising but remain to be substantiated. Serious infections are a concern.
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Thalidomide
This drug, initially marketed as a mild sedative but later stopped due to alarming teratogenic side effects, has recently been rediscovered as an immunomodulatory compound. Thalidomide has both anticytokine and antiangiogenic properties. It appears to have some degree of effect against chronic GVHD, but less so in acute GVHD. 15 In a prospective randomised trial, thalidomide was found to be effective, but had several side effects. It was concluded that thalidomide should be reserved for salvage treatment of chronic GVHD. 16 
Mesenchymal stem cells (MSC)
MSC are found in extremely low density in normal foetal, postnatal and adult bone marrow, and can be expanded in vitro. These cells are an important part of the bone marrow microenvironment, and also have stem cell properties. MSC can be driven into differentiation toward several cell types, such as chondrocytes, adipocytes, myocytes, rhabdoid cells, fibroblasts, etc. An important feature is their capability of attenuating immune reactions. For instance, it has recently been observed that allogeneic MSC fail to elicit a T-cell response in vitro. 17 Furthermore, human MSC fail to stimulate allogeneic PBMC or lymphocyte proliferation in mixed cell cultures, 18 and it has therefore been suggested that these cells can be transplanted regardless of HLA matching and without further immunosuppression.
A case report from our centre by Le Blanc et al 8 describes a 9-year-old boy with grade IV acute GVHD after allogeneic transplantation from a matched unrelated donor for ALL in third remission. He received ex vivo expanded MSC from his mother and promptly improved. After discontinuation of immunosuppression due to MRD positivity, the GVHD soon recurred (at grade IV) but could again be completely stopped with another dose of maternal MSC. The boy was subsequently discharged from hospital, but continued to have a low-grade acute/chronic GVHD and required maintained immunosuppression and steroids. It must be concluded that MSC therapy for severe acute GVHD hold great promise for the future. A prospective EBMT study investigating the use of ex vivoexpanded mesenchymal stem cells in sibling donar transplants is therefore now being launched.
Octreotide [3] [4] [5] This somatostatin analogue has a documented effect on diarrhoea and can be used as an adjuvant in gastrointestinal GVHD. The effect is often prompt, and is exerted through antagonism of neuropeptides in the gut, thus counteracting gut hypermotility and hypersecretion. However, there is so far no evidence for a curative effect against GVHD.
